Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Polverelli, Nicola  [Clear All Filters]
2018
Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leuk Res. 2018;74:86-88.
2019
Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, et al. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2019.
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MChiara, Caramella M, Rumi E, Carraro MCristina, Polverelli N, et al. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. Blood Adv. 2019;3(21):3196-3200.
2020
Bernardi S, Malagola M, Polverelli N, Russo D. Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?. Acta Haematol. 2020:1-2.
Malagola M, Bernardi S, Polverelli N, Russo D. Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?. Br J Haematol. 2020.
Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, et al. RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA. Hematol Oncol. 2020.
Piñana JLuis, Xhaard A, Tridello G, Passweg J, Kozijn A, Polverelli N, Heras I, Pérez A, Sanz J, Berghuis D, et al. Seasonal human coronaviruses respiratory tract infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2020.
Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020.
Lougaris V, Malagola M, Baronio M, Morello E, Gazzurelli L, Benvenuto A, Palumbo L, Moratto D, Girelli MFederica, Chiarini M, et al. Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion. Clin Immunol. 2020:108589.
2021
Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, et al. GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. Transplant Cell Ther. 2021.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JMoritz, Musso M, Giebel S, Uzay A, Langmuir P, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021;385(3):228-238.
Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, et al. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer. 2021.
2023
Hernández-Boluda JCarlos, Eikema D-J, Koster L, Kröger N, Robin M, de Witte M, Finke J, Finazzi MChiara, Broers A, Raida L, et al. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant. 2023.
Malagola M, Radici V, Farina M, Pellizzeri S, Spoldi F, Morello E, Polverelli N, Buttini EAccorsi, Bernardi S, Re F, et al. CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2023.
Malagola M, Radici V, Farina M, Pellizzeri S, Spoldi F, Morello E, Polverelli N, Buttini EAccorsi, Bernardi S, Re F, et al. Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2023.
Robin M, Gras L, Koster L, Gagelmann N, van Gorkom G, Ederr M, Itälä-Remes M, Zuckerman T, Beguin Y, Schaap N, et al. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2023.
Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian J-J, et al. Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem. 2023;4(3):679-689.
Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E, Polverelli N, Tiribelli M, Auteri G, Tieghi A, et al. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2023.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernández-Boluda JCarlos, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2023.
Ortí G, Gras L, Zinger N, Finazzi MChiara, Sockel K, Robin M, Forcade E, Avenoso D, Kröger N, Finke J, et al. Outcomes after Allogeneic Hematopoietic Cell Transplant in patients diagnosed with Blast Phase of Myeloproliferative Neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2023.
Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EMaria, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, et al. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Cancer. 2023.
2024
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson KMO, Salmenniemi U, Dreger P, Borne Pvon dem, Snowden JA, et al. Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024.
Polverelli N, Bonneville EF, de Wreede LC, Koster L, Kröger NMartin, Schroeder T, de Latour RPeffault, Passweg J, Sockel K, Broers AEC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. 2024.